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Objective: To express human vascular endothelial growth factor121 (VEGF121) in in-
sect cells.
Methods: A gene construct containing VEGF was cloned in the pFastBac-HTA vector,
followed by transformation in DH10BAC. The recombinant bacmid was then extracted,
and transfected into Sf9 insect cells. The transfected cells were harvested, and then VEGF
expression was conﬁrmed by western blotting using speciﬁc antibodies. The tube for-
mation assay was used for functional assessment of VEGF.
Results: Our results showed that VEGF could be successfully expressed in the bacu-
lovirus system. Puriﬁed VEGF was able to stimulate in vitro tube formation of human
endothelial cells.
Conclusions: Results from this study demonstrated that the recombinantly-produced
VEGF can be considered as a promising candidate for therapeutic purposes.1. Introduction
Angiogenesis refers to the formation and development of
new blood vessels from pre-existing blood vessels [1].
Angiogenesis is a rare phenomenon in healthy adult, which
only occur temporarily under speciﬁc physiological conditions
such as wound healing, inﬂammation and women's sexual
cycle [2,3]. A disruption in the balance between angiogenic and
anti-angiogenic factors leads to pathological angiogenesis [4–6].
There is strong evidence that tumor cells need new blood
vessels to grow, invasion and spread [7,8]; in the absence of
blood vessels, tumor cells can not exceed more than 1–2 mm
in size [9]. Vascular endothelial growth factor (VEGF) is the
most important angiogenic factor [4,10–12], which includes 5members in mammals such as VEGF-A, VEGF-B, VEGF-C,
VEGF-D and PlGE (Placental growth factor). VEGF-A, the
most important member of this family [13], interacts with two
receptors, VEGFR-2 and VEGFR-1, resulting in endothelial
cell proliferation and angiogenesis [14,15]. VEGF-A consists of 5
main isoforms with different amino acid residues, including
VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206.
Importantly, VEGF121 and VEGF165 are the most abundant
isoforms with 121 and 165 amino acid residues, respectively [16–
18]. These isoforms are found in the majority of cells expressing
the VEGF gene. The presence of exon 7 in the VEGF165 gene,
but not in the VEGF121 gene, enables VEGF165 to bind to
heparin, heparan sulfate and neuropilin-1(NP-1) receptor,
which play a role in the development of embryo [16]. The low
molecular mass of VEGF121 makes it soluble and freely
diffusible [19]. A variety of studies demonstrated that
VEGF121 displays full biological activities of larger isoforms
[19], emphasizing the role of VEGF121 as a potential target for
drug development. Difﬁculties in the production of
recombinant proteins, such as VEGF, in Escherichia coli
(E. coli) lead to the development of novel expression systems
such as the baculovirus expression system [20]. Insect cells arerticle under the CC BY-NC-ND license (http://
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animal proteins [21]. By deﬁnition, insect cell expression systems
that use insect viruses are considered as a baculovirus. Simply
stated, baculoviruses are a group of viruses that infect
vertebrates and insects [22]. One of the important advantages
of these systems over bacterial expression systems is to
mediate post-translational modiﬁcations such as phosphoryla-
tion, glycosylation and acylation. The formation and reduction
of disulﬁde bonds (proteolytic characteristics) result in the pro-
duction of recombinant proteins, which is structurally similar to
natural proteins. Another important beneﬁt of this system is to
allow low-cost production of recombinant proteins [23]. In this
regard, the aim of this study was to express VEGF in the
baculovirus system.
2. Material and methods
2.1. VEGF121 DNA construct preparation
The human VEGF121 gene was cloned in pET26b in our
previous study [24]. In the present study, we attempted to clone
hVEGF into the pFastBac HTA transfer plasmid (Bac-to-Bac
expression system). For this purpose, the hVEGF gene was
ampliﬁed with speciﬁc primers anchored with BamHI and
XhoI restriction enzyme sites (Table 1). Ampliﬁed hVEGF
was cloned in the pFastBac HTA vector. Subsequently, the
construct was transformed into E. coli TG1 competent cells, and
conﬁrmed. The ﬁdelity of cloned sequences was veriﬁed by
DNA sequencing; the resulting construct was named pFast-
hVEGF (Figure 1A).Table 1
Primers sequence.









Figure 1. A) Schematic structure of the VEGF gene in the plasmid pFastBac HT
of hVEGF121 in pFastBac HTA plasmid). D) Double digestion of pFast-hVEG
double digested. E) DNA electrophoresis of isolated recombinant bacmid (lane2.2. Transposition of the VEGF121 gene to baculovirus
bacmid
The pFast-hVEGF construct was transformed into DH10Bac
bacteria to establish recombinant baculovirus bacmid (Bac-to-
Bac baculovirus expression system). In the Bac-to-Bac baculo-
virus expression system, transposition generally occurs between
two areas of mini-Tn7 pFastBac and mini-att Tn7 baculovirus
Bacmid. Replacement of mini-Tn7 at the junction of Bacmid
results in LacZ disruption. Therefore, the recombinant Bacmid
was screened after 48 h using blue–white colony screening on
LB agar containing 50 mg/mL kanamycin, 25 mg/mL tetracycline
and 40 mg/mL gentamicin, and incubated at 37 C for 18 h.
Fidelity of the VEGF gene transferred into Bacmid was
conﬁrmed by PCR using M13 primers (Table 1). The recom-
binant bacmid was extracted from DH10Bac according to the
standard method [25], and used for transfection of Sf9 insect
cells.
2.3. Sf9 culture and transfection
Sf9 cells (obtained from National Cell Bank of Iran, Pasteur
Institute of Iran, Tehran, Iran) were cultured in Grace's insect
medium (Invitrogen, gibco) supplemented with 10% FBS,
100 U/mL of penicillin, 100 mg/mL of streptomycin, and
incubated at 27 C in a humidiﬁed incubator. The recombinant
bacmid construct was transfected to exponentially-growing Sf9
cells using a cellfectin (Invitrogen) transfection reagent ac-
cording to the manufacturer's instructions.
2.4. Recombinant baculovirus preparation
Cytopathic effects (CPEs) were detected 4 days after trans-
fection. The supernatant of Sf9 cells was collected (P1 or First
Generation of virus), and used to infect new Sf9 cells. The P1
virus was used for Sf9 transfection to establish P2 and P3. To
conﬁrm VEGF expression, cells transfected by P1, P2 and P3
were harvested after four days of infection. Then, expression of
recombinant VEGF121 was evaluated by SDS-PAGE and
western blotting on cell lysates. Avastin (Commercial Anti-
VEGF, at a dilution of 1:4000) and Anti-Human IgG HRP-
conjugated (at a dilution of 1:4000) were used as primary and
secondary antibodies in western blot analysis, respectively.a. B) Ampliﬁed hVEGF121 (400 bp). C) Colony-PCR results (after cloning
F resulting plasmid with BamHI and XhoI. Lane 1, undigested and lane 2,
s 1, 2) and non-recombinant bacmid (lane 3) with lambda phage marker.
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For VEGF puriﬁcation, a density of approximately 6 × 107
Sf9 transfected cells were harvested, and then suspended in
5 mL PBS. The cells were disrupted by three freeze/thaw cycles,
and subsequently suspended in lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole), followed by 15 ultra-
sonication treatments of 15 s each. The mixture was centrifuged
at 6000 × g for 30 min at 4 C to remove insoluble particles.
Supernatants were ﬁltered using 0.45 mm syringe ﬁlters, and
then loaded on the nickel afﬁnity column (QIAGEN, Germany).
The column was washed using washing buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole) to elute unbound
proteins. The recombinant His-tagged VEGF was eluted using
elution buffer (50 mM NaH2PO4, 300 mM NaCl, and 250 mM
imidazole). The puriﬁcation process was conﬁrmed by 15%
SDS-PAGE and western blot analysis. Expression levels were
detected by the Bradford assay.
2.6. Tube assay
For tube formation assay, we used primary HUVECs (Hu-
man Umbilical Vein Endothelial Cells) between passages 2 and
6, as isolated in our previous study [26]. A solution of Geltrex™
LDEV-Free Reduced Growth Factor Basement Membrane
(Gibco, Invitrogen) was thawed at 4 C, coated at a dose ofFigure 2. Blue–white colony screening for transformation of pFastBac-
VEGF in DH10Bac.
Figure 3. Transfection of Sf9 cells by recombinant bacmid DNA. A; non-tran
cytopathic effects (CPEs) were detected after 72 h of transfection.50 mL on a 96-well plate, and incubated at 37 C in a humaniﬁed
incubator for 30 min in order to solidify the Geltrex. 100 mL of
EBM-2 medium containing 5000 HUVEC cells with and
without of recombinant expressed VEGF was added to each
well. After 2, 4 and 6 h, cell conditions and tube formation were
monitored under an invert microscope (INV100-FL, BEL-Italy).
In addition, it is important to note that the assay was carried out
in triplicate.
3. Results
3.1. hVEGF121 ampliﬁcation and recombinant
baculovirus DNA preparation
As shown in Figure 1B, the ampliﬁed human VEGF121
(400 bp) was detected in gel electrophoresis. hVEGF121 and
pFastBac were digested with BamHІ and XhoІ, ligated and
transformed into E. coli TG1 competent cells. Approximately 24
colonies were screened by colony-pcr, 21 colonies of which
contained recombinant hVEGF121 (Figure 1C). In addition,
BamHІ and XhoІ double digestion (Figure 1D) and sequencing
conﬁrmed the ﬁdelity of recombinant hVEGF121. Finally, re-
combinant pFast-hVEGF121 was transformed into DH10Bac,
and recombinant baculoviral DNA resulted from the Bac-to-Bac
baculovirus expression system. Results from PCR, carried out
on baculovirus plasmid, showed that recombinant baculovirus
yielded a band of 2740 bp (Figures 1E and 2E).
3.2. Transfection of Sf9 cells
Transfection of Sf9 cells was conﬁrmed by the recombinant
baculovirus (Figure 2). After 72-h post transfection, cytopathic
effects (CPEs) were found in transfected Sf9 cells as compared
to non-transfected Sf9 cells (control cells), indicating the suc-
cessful transfection (Figure 3A). The cells transfected with re-
combinant baculovirus showed CPEs of nucleus enlargement
and granulation (Figure 3B).
3.3. Expression and puriﬁcation of recombinant hVEGF
After 3 days of Transfection when CPEs were observed, Sf9
cells were harvested, and expression of hVEGF121 was evalu-
ated by using 15% SDS-PAGE and western blot analysis. Assfected Sf9. B; Sf9 cells were transfected by recombinant baculovirus, and
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cells; two protein bands (15–40 kDa) indicate different glyco-
sylated forms of the protein. For hVEGF121 puriﬁcation,
6 × 107 of Sf9 cells were disrupted by sonication, and cell debris
was removed by centrifugation. The supernatant was loaded on
the Ni-NTA column, and recombinant protein was eluted by
imidazole 250 mM. The yield of puriﬁed recombinant VEGF121
per liter of Sf9 cells was about 500 mg.
3.4. Tube formation assay
The ﬁndings from this study indicated that recombinant
VEGF121 has the ability to increase tube formation in
HUVECs. As shown in Figure 5, VEGF121-treated HUVECs
were able to form tube-like structures. By contrast, there were no
tube like structures in control cells (HUVECs with no VEGF).
The cells were stained with calcein AM (Trevigen) according to
the manufacturer's protocols.Figure 4. A) SDS-PAGE results, 1; transfected cells, 2; non-transfected cells. A
different glycosylation patterns. B) Western blot analysis with bevacizumab an
protein marker.
Figure 5. Tube assay result. A) The lack of VEGF. B) The presence of VEGF4. Discussion
Nowadays, there is a worldwide demand for recombinant
protein production, as one of the main interest of pharmaceutical
industries [27]. The most important decisions in the selection of
recombinant protein production and puriﬁcation are related to
the host that affects product quality. To choose an appropriate
host, some important criteria must be considered, including the
amount of product required, toxicity, ease of puriﬁcation and
biological activity of the product [28]. There had been several
expression systems, each with its own advantages and
disadvantages. Today, the E. coli expression system is the most
commonly used expression system for recombinant protein
production. The best-known beneﬁts for this system are the
ability to grow fast, simple and cheap requirements, high-density
environments, well-known genetics and molecular biology, and
the capability to express high levels of recombinant proteins
[29,30]. However, There are some critical disadvantages for thiss it can be seen, there is two bands in transfected Sf9 cells (lane 1) showing
tibodies. lane 1: the puriﬁed hVEGF121, lane 2: the negative control. M;
. Tube-like structures were formed in the presence of VEGF as a simulator.
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modiﬁcations (such as glycosylation), improper recombinant
protein folding and secretory mechanisms, as well as inefﬁcient or
low efﬁcient disulﬁde bond formation. Another useful expression
system is a mammalian expression system. Although protein
produced in mammalian expression systems lacks the limitations
of bacterial expression system, the main disadvantage of
mammalian systems is their need for expensive cell culture [31].
However, baculovirus is one of the common systems for
recombinant production of proteins. Here, for the ﬁrst time, we
successfully expressed hVEGF121 in the baculovirus system.
In addition, the ability of VEGF to stimulate endothelial cells
was evaluated by the Tube formation assay.
Conﬂict of interest statement
The authors declare no conﬂict of interest.
Acknowledgments
This work was supported ﬁnancially by Iran National Science
Foundation (INSF), grant number 91004026.
References
[1] Krishna Priya S, Nagare RP, Sneha VS, Sidhanth C, Bindhya S,
Manasa P, et al. Tumour angiogenesis-origin of blood vessels. Int J
Cancer 2016; 139(4): 729-735.
[2] Shimizu T, Hoshino Y, Miyazaki H, Sato E. Angiogenesis and
microvasculature in the female reproductive organs: physiological and
pathological implications. Curr Pharm Des 2012; 18(3): 303-309.
[3] Li J, Hampton T, Morgan J, Simons M. Stretch-induced VEGF
expression in the heart. J Clin Invest 1997; 100(1): 18.
[4] Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of
angiogenesis in solid tumours: an overview. Eur J Intern Med
2009; 20(7): 663-671.
[5] Seko Y, Nishimura H, Takahashi N, Ashida T, Nagai R. Serum
levels of vascular endothelial growth factor and transforming
growth factor-beta 1 in patients with atrial ﬁbrillation undergoing
deﬁbrillation therapy. Jpn Heart J 2000; 41(1): 27-32.
[6] Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological,
prognostic, and growth-factor pathways and their link to trial
design and anticancer drugs. Lancet Oncol 2001; 2(5): 278-289.
[7] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.
Nature 2000; 407(6801): 249-257.
[8] Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U,
Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents
effective angiogenesis and inhibits tumor growth. Nat Med 2002;
8(12): 1369-1375.
[9] Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel
antiangiogenic strategies. Int J Cancer 2010; 126(8): 1777-1787.
[10] Folkman J, Merler E, Abernathy C, Williams G. Isolation of a
tumor factor responsible for angiogenesis. J Exp Med 1971;
133(2): 275-288.
[11] Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Under-
standing the biology of angiogenesis: review of the most important
molecular mechanisms. Blood Cells Mol Dis 2007; 39(2): 212-220.
[12] Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of
vascular endothelial growth factors. Cardiovasc Res 2005; 65(3):
550-563.[13] Pradeep C, Sunila E, Kuttan G. Expression of vascular endothelial
growth factor (VEGF) and VEGF receptors in tumor angiogenesis
and malignancies. Integr Cancer Ther 2005; 4(4): 315-321.
[14] Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-
receptor signal transduction. Trends Biochem Sci 2003; 28(9):
488-494.
[15] Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF
receptor signalling? In control of vascular function. Nat Rev Mol
Cell Biol 2006; 7(5): 359-371.
[16] Yue X, Tomanek RJ. Effects of VEGF165 and VEGF121 on
vasculogenesis and angiogenesis in cultured embryonic quail
hearts. Am J Physiol Heart Circ Physiol 2001; 280: 2240-2247.
[17] Dulak J, Jo´zkowicz A, Ratajska A, Szuba A, Cooke JP, Dembin-
ska-Kiec Aldona. pSG5VEGF plasmids in vascular smooth muscle
cells vascular endothelial growth factor is efﬁciently synthesized in
spite of low transfection efﬁciency of pSG5VEGF plasmids in
vascular smooth muscle cells. Vasc Med 2000; 5: 33-40.
[18] Kim S, Mohamedali KA, Cheung LH, Rosenblum MG. Over-
expression of biologically active VEGF121 fusion proteins in
Escherichia coli. J Biotechnol 2007; 128: 638-647.
[19] Liu Y, Cheung LH, Thorpe P, Rosenblum M. Mechanistic studies
of a novel, human fusion toxin composed of vascular endothelial
growth factor (VEGF)121 and the serine protease granzyme B:
directed apoptotic events in vascular endothelial cells. Mol Cancer
Ther 2003; 2: 949-959.
[20] Kidd IM, Emery VC. The use of baculoviruses as expression
vectors. Appl Biochem Biotechnol 1993; 42(2–3): 137-159.
[21] Ghosh S, Parvez K, Banerjee K, Sarin SK, Hasnain SE. Baculo-
virus as mammalian cell expression vector for gene therapy: an
emerging strategy. Mol Ther 2002; 6(1): 5-10.
[22] Shao-Hua C, Hong-Liang S, Zuo-Hu L. Effect of temperature
oscillation on insect cell growth and baculovirus replication. Appl
Environ Microbiol 1998; 64(6): 2237-2239.
[23] Jarvis DL, Kawar ZS, Hollister JR. Engineering N-glycosylation
pathways in the baculovirus-insect cell system. Curr Opin Bio-
technol 1998; 9(5): 528-533.
[24] Kazemi-Lomedasht F, Behdani M, Pooshang Bagheri K, Habibi
Anbouhi M, Abolhassani M, Khanahmad H, et al. Expression and
puriﬁcation of functional human vascular endothelial growth
factor-a121; the most important angiogenesis factor. Adv Pharm
Bull 2014; 4(4): 323-328.
[25] Carmo A, Giovanni D, Correˆa T, Martins L, Stocco R, Suazo C,
et al. Expression of an antiviral protein from Lonomia obliqua
hemolymph in baculovirus/insect cell system. Antivir Res 2012;
94(2): 126-130.
[26] Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-
Anbouhi M, Abolhassani M, Arezumand R, et al. Inhibition of
angiogenesis in human endothelial cell using VEGF speciﬁc
nanobody. Mol Immunol 2015; 65(1): 58-67.
[27] Assenberg R, Wan PT, Geisse S, Mayr LM. Advances in recom-
binant protein expression for use in pharmaceutical research. Curr
Opin Struct Biol 2013; 23(3): 393-402.
[28] LaVallie ER, McCoy JM. Gene fusion expression systems in
Escherichia coli. Curr Opin Biotechnol 1995; 6(5): 501-506.
[29] Chen R. Bacterial expression systems for recombinant protein
production: E. coli and beyond. Biotechnol Adv 2012; 30(5): 1102-
1107.
[30] Shokrollahi N, Shahbazzadeh D, Pooshang-Bagheri K, Habibi-
Anbouhi M, Jahanian-Najafabadi A, Behdani M. A model to study
the phenotypic changes of insect cell transfection by copepod super
green ﬂuorescent protein (cop-GFP) in baculovirus expression
system. Iran Biomed J 2016; 20(3): 182-186.
[31] Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol
2010; 28(9): 917-924.
